DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
 Print  Email    

Allergan Inc. (AGN) Seeks to Sell Lap-Band and Obesity Unit by June


2/6/2013 7:28:10 AM

Allergan Inc. (AGN), the maker of the Botox wrinkle treatment, said it’s committed to selling the company’s obesity-treatment unit in the first half of 2013 after completing a review of the business. The unit, dominated by the Lap-Band weight loss device, has been reclassified as a discontinued operation, resulting in an unspecified charge to write down assets to fair value, Irvine, California-based Allergan said in a statement today. Chief Executive Officer David Pyott said last month he wanted to sell the business by the end of the first quarter and that the unit has attracted interest, including from a private-equity company. The obesity unit’s sales tumbled 22 percent in the fourth quarter to $36.8 million, Allergan said today. The unit’s annual revenue has plummeted from a peak of $296 million in 2009 because of questions about the risks from the Lap-Band and lawsuits stemming from surgeries that went awry. The obesity market once generated about a third of Allergan’s U.S. sales. “We are dynamically managing our portfolio to drive long- term sales growth,” Pyott said in the statement.

Read at BusinessWeek
Read at Los Angeles Times
Read at News Release

 Read Article at  Related Companies  News Categories
   


ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 
    

//-->